BR112018001980A2 - compostos cíclicos úteis como moduladores de tnf alfa - Google Patents

compostos cíclicos úteis como moduladores de tnf alfa

Info

Publication number
BR112018001980A2
BR112018001980A2 BR112018001980A BR112018001980A BR112018001980A2 BR 112018001980 A2 BR112018001980 A2 BR 112018001980A2 BR 112018001980 A BR112018001980 A BR 112018001980A BR 112018001980 A BR112018001980 A BR 112018001980A BR 112018001980 A2 BR112018001980 A2 BR 112018001980A2
Authority
BR
Brazil
Prior art keywords
compounds useful
cyclic compounds
compounds
alpha tnf
modulators
Prior art date
Application number
BR112018001980A
Other languages
English (en)
Inventor
Jiang Bin
Xiao Hai-Yun
Duan Jingwu
G Murali Dhar T
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112018001980A2 publication Critical patent/BR112018001980A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Abstract

a presente invenção refere-se a compostos de fórmula (l) ou um sal do mesmo, em que: o anel a é anel carbocíclico ou heterocíclico de 3 a 6 membros; x é cr1 ou n; y é ?(cr5r5)m-; z é ?(cr5r5)n-; e q, r1, r2, r3, r4, r6, r7, r8, r9, e r10 são definidos. também refere-se aos métodos de uso de tais compostos como moduladores de tnfa, e composições farmacêuticas compreendendo tais compostos. estes compostos são úteis no tratamento de doenças inflamatórias e autoimunes.
BR112018001980A 2015-08-03 2016-08-02 compostos cíclicos úteis como moduladores de tnf alfa BR112018001980A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200415P 2015-08-03 2015-08-03
PCT/US2016/045104 WO2017023902A1 (en) 2015-08-03 2016-08-02 Cyclic compounds useful as modulators of tnf alpha

Publications (1)

Publication Number Publication Date
BR112018001980A2 true BR112018001980A2 (pt) 2018-09-18

Family

ID=56610045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001980A BR112018001980A2 (pt) 2015-08-03 2016-08-02 compostos cíclicos úteis como moduladores de tnf alfa

Country Status (13)

Country Link
US (1) US10335392B2 (pt)
EP (1) EP3331889B1 (pt)
JP (1) JP6811233B2 (pt)
KR (1) KR20180031773A (pt)
CN (1) CN108137609B (pt)
AU (1) AU2016301215A1 (pt)
BR (1) BR112018001980A2 (pt)
CA (1) CA2994703A1 (pt)
EA (1) EA201890421A1 (pt)
ES (1) ES2828696T3 (pt)
IL (1) IL257159A (pt)
MX (1) MX2018001173A (pt)
WO (1) WO2017023902A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168641A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Tricyclic modulators of tnf signaling
TW201702247A (zh) 2015-04-17 2017-01-16 艾伯維有限公司 作為ｔｎｆ信號傳遞調節劑之吲唑酮
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CA3179702A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
MX2022013657A (es) 2020-05-05 2023-02-01 Nuvalent Inc Quimioterápicos de éter macrocíclico heteroaromático.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5149386A (ja) * 1974-10-28 1976-04-28 Hitachi Ltd Shuchukanshiseigyohoho
WO1998037072A1 (en) 1997-02-25 1998-08-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
JPH11228539A (ja) * 1997-12-03 1999-08-24 Taisho Pharmaceut Co Ltd 含窒素四環性化合物
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
WO2003064422A1 (fr) 2002-01-31 2003-08-07 Daiichi Pharmaceutical Co., Ltd. Derive imidazo[1,2-a]pyridine
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2014009295A1 (en) 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
KR101669334B1 (ko) * 2013-09-30 2016-10-25 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3080085B1 (en) 2013-12-09 2019-08-14 UCB Biopharma SPRL Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2809535T3 (es) 2013-12-09 2021-03-04 UCB Biopharma SRL Derivados de imidazopiridina como moduladores de la actividad de TNF
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
SI3204386T1 (sl) 2014-10-06 2021-08-31 Signal Pharmaceuticals, Llc Substituirane spojine aminopurina, njihove sestave in načini zdravljenja v povezavi z njimi
CA2980161A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf
EA032315B1 (ru) 2015-03-18 2019-05-31 Бристол-Маерс Сквибб Компани Замещенные трициклические гетероциклические соединения
EP3271361B1 (en) 2015-03-18 2020-04-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf

Also Published As

Publication number Publication date
US10335392B2 (en) 2019-07-02
WO2017023902A1 (en) 2017-02-09
EP3331889B1 (en) 2020-09-23
EA201890421A1 (ru) 2018-07-31
KR20180031773A (ko) 2018-03-28
US20180221344A1 (en) 2018-08-09
JP2018525377A (ja) 2018-09-06
JP6811233B2 (ja) 2021-01-13
MX2018001173A (es) 2018-04-24
CN108137609B (zh) 2021-07-16
ES2828696T3 (es) 2021-05-27
CA2994703A1 (en) 2017-02-09
EP3331889A1 (en) 2018-06-13
CN108137609A (zh) 2018-06-08
AU2016301215A1 (en) 2018-03-22
IL257159A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
BR112018001980A2 (pt) compostos cíclicos úteis como moduladores de tnf alfa
BR112018001960A2 (pt) compostos heterocíclicos úteis como moduladores de tnf alfa
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
CL2016001364A1 (es) Moduladores de ror gamma (rory)
BR102015032361A8 (pt) Compostos de quinazolina, usos dos mesmos, composição farmacêutica, kit e artigo de manufatura
BR112017019731A2 (pt) compostos heterocíclicos tricíclicos úteis como inibidores de tnf
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
MD4516C1 (ro) Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici
BR112017019773A2 (pt) compostos heterocíclicos tricíclicos substituídos
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
BR112017019605A2 (pt) compostos heterocíclicos úteis como inibidores de tnf
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
UY35661A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen
BR112015015654A2 (pt) monômeros fluorescentes e polímeros de tratamento marcados contendo os mesmos para o uso em sistemas de água industriais
CL2015002897A1 (es) Inhibidores de bace1
BR112015013485A2 (pt) derivados de benzilsulfonamida como moduladores de rorc
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
ECSP17007336A (es) Compuestos de imidazopiridazina
MX2017015740A (es) Moduladores de ror gamma (ror?).
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
MX2016005128A (es) Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes.
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CY1121247T1 (el) Νεες ενωσεις ισοϊνδολινης ή ισοκινολινης, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτες

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]